New Key Statistics Module, Z-Score and F-Score
XAMS:PHARM Key Ratios
Market Cap € M | 584.54 |
Enterprise Value € M | 552.34 |
P/E(ttm) | -- |
PE Ratio without NRI | -- |
Forward PE Ratio | -- |
Price/Book | 3.09 |
Price/Sales | 2.66 |
Price/Free Cash Flow | -- |
Price/Owner Earnings | -- |
Payout Ratio % | -- |
Revenue (TTM) € M | 238.00 |
EPS (TTM) € | -0.01 |
Beneish M-Score | -2.59 |
10-y EBITDA Growth Rate % | -- |
5-y EBITDA Growth Rate % | -19.10 |
y-y EBITDA Growth Rate % | -23.50 |
EV-to-EBIT | -84.18 |
EV-to-EBITDA | 48.23 |
PEG | -- |
Shares Outstanding M | 673.44 |
Net Margin (%) | -4.13 |
Operating Margin % | -9.57 |
Pre-tax Margin (%) | -4.58 |
Quick Ratio | 1.16 |
Current Ratio | 1.43 |
ROA % (ttm) | -2.43 |
ROE % (ttm) | -5.14 |
ROIC % (ttm) | -11.12 |
Dividend Yield % | -- |
Altman Z-Score | 1.51 |
XAMS:PHARM Number of Guru Trades
XAMS:PHARM Volume of Guru Trades
Gurus Latest Trades with XAMS:PHARM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
XAMS:PHARM is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Pharming Group Insider Transactions
No Available Data